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Abstract
This study evaluated the interferon-free, oral combination of deleobuvir (non-nucleoside
HCV NS5-RNA-polymerase inhibitor) and faldaprevir (HCV NS3/4A-protease inhibitor) with
ribavirin in patients with HCV genotype-1b and moderate (Child-Pugh B [CPB], n = 17) or
mild hepatic impairment (Child-Pugh A [CPA], n = 18). Patients received faldaprevir 120 mg
and deleobuvir (600 mg [CPA], 400 mg [CPB]) twice-daily with weight-based ribavirin for
24 weeks. Baseline characteristics were similar between groups. Among CPA patients,
13/18 completed treatment; discontinuations were for adverse events (AEs, n = 1), lack of
efficacy (n = 3) and withdrawal (n = 1). Among CPB patients, 8/17 completed treatment; dis-
continuations were for AEs (n = 6), withdrawal (n = 1) and ‘other’ (n = 2). Sustained virologic
response at post-treatment Week 12 (SVR12) was achieved by 11 (61%) CPA patients
(95% confidence interval: 38.6%–83.6%) and 9 (53%) CPB patients (95% confidence inter-
val: 29.2%–76.7%), including most CPA (11/16) patients with Week 4 HCV RNA <25 IU.mL-1
(target detected or not detected) and most CPB (8/9) patients with Week 4 HCV RNA <25
IU.mL-1 (target not detected); 0/4 CPB patients with Week 4 HCV RNA <25 IU.mL-1 (target
detected) achieved SVR12. The most common AEs in both groups were nausea, diarrhoea
and vomiting. Serious AEs were observed in 9 (53%) CPB patients and 1 (6%) CPA patient.
Plasma trough concentrations of deleobuvir and faldaprevir were not substantially different
between the CPA and CPB groups. In conclusion, in this small study the safety and efficacy
profiles for 24 weeks of treatment with faldaprevir+deleobuvir+ribavirin in patients with mild
or moderate hepatic impairment were consistent with the safety and efficacy profile of this
regimen in non-cirrhotic patients. Faldaprevir+deleobuvir+ribavirin resulted in SVR12 in
53–61% of patients: proportions achieving SVR4 but not SVR12 were higher than in non-
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cirrhotic patients and overall response rates were lower than rates reported with other all-
oral regimens in patients with cirrhosis.
Trial Registration: ClinicalTrials.gov NCT01830127.
Introduction
Chronic infection with hepatitis C virus (HCV) is a major cause of morbidity and mortality
worldwide [1–3]. The most prevalent HCV genotype in North America and Europe, HCV
genotype-1 (GT-1), has historically been difficult to treat with what was for many years the
standard-of-care: peginterferon-α (PegIFN) and ribavirin [2, 4, 5]. In addition to poor efficacy
against HCV GT-1, PegIFN is also poorly tolerated by many patients and has several contrain-
dications such as neuropsychiatric disorders, low white blood cell count or platelet count and
autoimmune disease [2]. Over the past decade, improvements in the understanding of the
HCV lifecycle have led to the development of numerous oral direct-acting antiviral agents
(DAAs) that act on several different viral targets, including NS3/4A serine protease, NS5B
RNA polymerase and the multifunctional NS5A protein [2]. Initially treatment regimens using
DAAs continued to rely on combination with PegIFN [6, 7]. More recently, recognising the
limitations of PegIFN and the substantial improvements in simplicity, tolerability and efficacy
of DAA treatment, attention is increasingly focusing on combining DAAs in IFN-free treat-
ment strategies [8]. This field continues to rapidly evolve, with many novel agents and combi-
nation therapies now approved or in advanced stages of development [6, 7, 8].
Faldaprevir is an HCV NS3/4A protease inhibitor with a pharmacokinetic profile that
supports once-daily dosing and potent in vitro activity against HCV genotype subtypes 1a
and 1b [9, 10]. Deleobuvir is a non-nucleoside inhibitor of HCV NS5B RNA polymerase,
which binds reversibly to the thumb-pocket I of NS5B resulting in potent and specific anti-
viral activity [11, 12]. In vitro and Phase 1 clinical study data show that deleobuvir is more
active against GT-1b than against GT-1a [11, 12]. The IFN-free combination of once-daily
faldaprevir, twice-daily deleobuvir and ribavirin, has been investigated in phase 2 and Phase
3 clinical studies in treatment-naïve patients with chronic HCV GT-1 infection [13–16].
Phase 3 studies of this combination assessed 16 or 24 weeks’ treatment in HCV genotype-
1b-infected, treatment-naïve patients, including patients with compensated cirrhosis. After
24 weeks’ treatment, adjusted rates of sustained virologic response at 12 weeks post treat-
ment (SVR12) were 81% among patients without cirrhosis and 72–74% among patients
with cirrhosis (significantly higher than historical controls in both cases) [16]. Treatment of
patients without cirrhosis for 16 weeks resulted in high relapse rates and lower SVR rates
(72%-76%) [16].
In patients with chronic HCV infection and decompensated cirrhosis, anti-HCV treatment
is important since achieving an SVR reduces the risk of clinical decompensation and hepato-
cellular carcinoma and can prevent otherwise certain reinfection following liver transplant [2,
17]. The objectives of the current study were to evaluate the pharmacokinetic profile and safety
of deleobuvir in combination with once-daily faldaprevir and weight-based ribavirin in a small
group of patients with moderate hepatic impairment (Child-Pugh B [CPB]) compared with
patients with mild hepatic impairment (Child-Pugh A [CPA]). Based on the results of phase 3
trials in treatment-naïve patients [16], the development of faldaprevir in combination with
deleobuvir has been halted. However, faldaprevir has been licensed to another company and
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continues development, with phase 2 clinical studies of faldaprevir in combination with other
novel DAAs initiated (ClinicalTrials.gov NCT02716428 and NCT02593162).
Materials and Methods
Study design and patient population
This was an open-label, phase 2b study recruiting both treatment-naïve and treatment-experi-
enced HCV genotype-1b-infected patients at multiple clinical centres in Europe and North
America (ClinicalTrials.gov NCT01830127). The key inclusion criteria were: age 18–75 years;
HCV RNA1000 IU.mL-1 at screening; liver cirrhosis with Metavir Grade 4 or Ishak5 on
biopsy, or liver stiffness of13 kPa on fibroscan; patients who were pegylated IFN/ribavirin
treatment-experienced must have experienced relapse, partial response, or intolerance before
week 12 of treatment. The key exclusion criteria were: HIV or HBV co-infection; confirmed or
suspected malignancy (current or within 5 years); total bilirubin>3 mg/dL, serum albumin
<2.4 g.dL-1 and international normalized ratio>2.3; Child-Pugh C.
The protocol was approved by the Institutional Review Board or Independent Ethics Com-
mittee of all participating sites (Ethikkommission der Medizinischen Hochschule Hanover;
Hospital Universitario Puerta de Hierro de Majadahonda, CEIC; CEIC Hospital Clı́nic de Bar-
celona, Agencia de Ensayos Clı́nicos, Servicio de Farmacia; Hospital Carlos III Comité Ético
de Investigación Clı́nica, CEIC Hospital Universitario la Paz, Paseo de la Castellana; CEIC
Hospital Universitari Vall d´Hebrón, Unidad de Soporte al CEIC (SCEI), Vall d´Hebrón Insti-
tut de Recerca (VHIR); Consorcio Hospital General, Universitario de Valencia Comité, Ético
de Investigación Clı́nica; NRES Committee; Chesapeake IRB). All patients provided written
informed consent. The trial took place between 24 April 2013 and 21 October 2014 and was
carried out in accordance with the principles of the Declaration of Helsinki.
Treatment
All patients received faldaprevir 120 mg (once-daily, with an additional 120 mg loading dose
on Day 1) and weight-based ribavirin (twice-daily). In addition, patients were assigned to two
different doses of deleobuvir based on their hepatic impairment status: CPA patients were
treated with deleobuvir 600 mg twice-daily and CPB patients were treated with deleobuvir 400
mg twice-daily. All treatments were taken orally and were self-administered by the patients.
Faldaprevir was taken in the morning together with deleobuvir and ribavirin, and together
with food. The evening doses of deleobuvir and ribavirin were taken together with food 12
hours after the morning dose. All patients were treated for 24 weeks and followed up for 12
weeks after the end of treatment.
Assessments
The primary efficacy endpoint was SVR12, defined as plasma HCV RNA level<25 IU.mL-1 12
weeks after end of treatment. SVR4 was a secondary endpoint. Plasma HCV RNA level was
measured using the quantitative Roche COBAS1 Taqman HCV/HPS assay (Version 2), with
a limit of detection between 10 and 20 IU/mL and a linear range of 25 IU/mL to 3.91 x 108 IU/
mL. Safety was assessed by monitoring adverse events (AEs, reported using the MedDRA cod-
ing dictionary version 17.1 and the NIH NIAID Division of AIDS [DAIDS] grading system),
AEs leading to treatment discontinuation, serious AEs (SAEs), laboratory test abnormalities,
and changes in laboratory test values. Pre-dose plasma trough concentrations for deleobuvir
and faldaprevir were measured at Week 1 through Week 4. A validated high-performance liq-
uid chromatography–tandem mass spectrometry (HPLC-MS/MS) assay was used to analyze
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the plasma samples (Tandem Labs, Salt Lake City, UT, USA). The faldaprevir and deleobuvir
methods were validated for a range of 10.0 to 10,000 ng/ml and 23.0 to 23,000 nmol/L respec-
tively; analyte quantitation in both methods was performed using a weighted (1/x2) linear least
squares regression analysis generated from calibration standards.
Statistical analysis
All efficacy, safety and pharmacokinetic endpoints were analyzed in a descriptive manner
using SAS1 Version 9.2. The primary efficacy analysis was carried out on an intent-to-treat
basis. Secondary efficacy and safety analyses were carried out for patients who received at least
one dose of study treatment. Patients who discontinued from the trial without reaching the
SVR time points were counted as treatment failures. Patients with missing SVR4 were imputed
by SVR12, if available. Missing SVR12 data were treated as failure.
Pharmacokinetic results are provided as geometric means. The coefficient of variation of







The objective of the pharmacokinetic analysis was to determine if the doses of faldaprevir
and deleobuvir administered to CPB patients provided trough levels equal to those seen in
CPA patients. For this analysis a sample size of 15 patients per arm was sufficient to provide
67% power (with a coefficient of variation of 100%) to detect differences when alpha = 0.1 and
the lower equivalence bound of the trough ratio was set at 0.5 and upper bound set at 2.
Results
Of the 64 patients who were enrolled, 35 were assigned to treatment: 18 in the CPA group and
17 in the CPB group. Of the 29 enrolled patients who were never treated, 24 were screening
failures and 5 withdrew from the study for unspecified reasons. Of the 18 treated patients in
the CPA group, 13 completed treatment. Reasons for discontinuation were: 1 AE, 3 lack of effi-
cacy and 1 withdrawal. Of the 17 treated patients in the CPB group, 8 completed treatment
(Fig 1). Reasons for discontinuation were: 6 AEs, 1 withdrawal and 2 ‘other’. Efficacy and
safety analyses were carried out for all 35 patients who were assigned to treatment. A total of 6
patients had at least one important protocol violation: 3 patients did not receive the additional
faldaprevir loading dose on Day 1; a further 3 patients were assigned to the wrong dose of
deleobuvir (based on their hepatic impairment status) and were excluded from the pharmaco-
kinetic analysis population.
Most patients were male (20/35), all were white, the mean age was 57.2 (standard deviation
[SD] 9.1) years and the mean BMI was 28.8 (SD 5.6) kg.m-2. Baseline characteristics of these
patients were similar between groups (Table 1).
Mean treatment exposures were 141 (SD 49) days for CPA patients and 114 (SD 65) days
for CPB patients. The majority of CPA patients (12/18) had24 weeks of exposure compared
with 5/17 CPB patients; the majority of CPB patients (10/17) had16 weeks of exposure.
SVR12 was achieved by comparable proportions of CPA and CPB patients (Table 2). The
majority of CPA (11/16) and CPB (8/13) patients with Week 4 HCV RNA levels<25 IU.mL-1
achieved SVR12. Of 9 and 7 CPA patients who had aWeek 4 HCV RNA levels<25 IU.mL-1
(undetected and detected, respectively), the majority (66.7% [n = 6] and 71.4% [n = 5], respec-
tively) achieved SVR12. Of the 9 CPB patients who had Week 4 HCV RNA<25 IU.mL-1
(undetected), 88.9% (n = 8) achieved SVR12. None of the 4 CPB patients with Week 4 HCV
RNA levels<25 IU.mL-1 (detected) achieved SVR12.
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Fig 1. Patient disposition. AE, adverse event; CPA, Child-Pugh A group; CPB, Child-Pugh B group.
doi:10.1371/journal.pone.0168544.g001
Table 1. Patient baseline characteristics.
CPA (N = 18) CPB (N = 17)
Male, n (%) 10 (56) 10 (59)
Mean age, years (SD) 57.8 (8.8) 56.6 (9.7)
Race: white, n (%) 18 (100) 17 (100)
Mean BMI, kg.m-2 (SD) 28.6 (6.1) 29 (5.1)













Mean HCV RNA, log10(IU).mL
-1, (SD) 6.5 (0.6) 6.2 (0.4)
HCV RNA800,000 IU.mL-1, n (%) 14 (78) 12 (71)
CPA, Child-Pugh A; CPB, Child-Pugh B; SD, standard deviation.
doi:10.1371/journal.pone.0168544.t001
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AE data are summarized in Table 3. The most common AEs in both groups were gastroin-
testinal: nausea, diarrhoea and vomiting. The majority of gastrointestinal events were mild or
moderate with only two DAIDS grade 3 events (upper abdominal pain, leading to treatment
discontinuation, in one CPB patient; diarrhoea and vomiting in a second patient). AE data are
summarized in Table 3.
Compared with CPA patients, a higher proportion of CPB patients reported serious AEs
(SAE), AEs leading to discontinuation of study treatment and DAIDS Grade 3/4 AEs. There
was one SAE in the CPA group, an upper gastrointestinal haemorrhage, which was considered
related to study treatment. In the CPB group, there were 9 SAEs; those that occurred in more
than 1 patient were: hepatic encephalopathy (4 patients, 2 related to treatment); and hepatic
cirrhosis (3 patients, all related to treatment). Other SAEs considered to be related to treatment
included diarrhoea, vomiting, and general physical health deterioration in one patient, and
hyponatraemia in a second patient. No patients died during the treatment period or through
the 28-day follow-up.
Plasma deleobuvir and faldaprevir trough concentrations are summarized in Table 4. Over-
all, after multiple oral doses, both deleobuvir and faldaprevir pre-dose plasma concentrations
were not substantially different in CPA and CPB patients up toWeek 4. Variability (gCV%)
was generally high, particularly for the CPA group.
Discussion
In this small study in treatment-naïve and treatment-experienced patients with chronic HCV
genotype-1b infection and mild or moderate hepatic impairment, the overall safety and effi-
cacy profiles for 24 weeks of treatment with deleobuvir and faldaprevir in combination with
ribavirin were generally consistent with the safety and efficacy profiles observed in non-cir-
rhotic patients [16]. Overall the majority of patients achieved SVR4 (74%) and SVR12 (57%);
however, response rates were lower than rates achieved with other all-oral DAA regimen in
HCV-infected patients with cirrhosis (>90% SVR12) [18, 19]. Notably, the trough concentra-
tions of deleobuvir and faldaprevir over 4 weeks of treatment were not substantially different
between the CPA and CPB groups and similar proportions of patients achieved SVR4 and
SVR12. The proportion of patients who were SVR4 but not SVR12 responders was higher than
reported in phase 3 studies in non-cirrhotic patients. In non-cirrhotic patients, 95% of patients
achieving SVR4 went on to achieve SVR12 [16]; whereas, in the present study, only 77% (20/
26) of patients with SVR4 also achieved SVR12 (Table 2). This is consistent with data from
other all-oral combinations that require longer treatment durations (24 weeks rather than 12
Table 2. Efficacy results.
Efficacy parameter CPA (N = 18) CPB (N = 17)
n/N (%) 95% CI n/N (%) 95% CI
Patients achieving SVR
SVR12 11/18 (61) 38.6–83.6 9/17 (53) 29.2–76.7
SVR4 13/18 (72) 51.5–92.9 13/17 (77) 56.3–96.6
SVR12 by Week 4 HCV RNA
<25 IU.mL-1, target not detected 6/9 (67) 8/9 (89)
<25 IU.mL-1, target detected 5/7 (71) 0/4 (0)
25 IU.mL-1 0/1 (0) 1/1 (100)
Missing 0/1 (0) 0/3 (0)
CPA, Child-Pugh A; CPB, Child-Pugh B; SD, standard deviation; SVR, sustained virologic response.
doi:10.1371/journal.pone.0168544.t002
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Table 3. Summary of treatment-emergent AEs.
Patients with an event, n (%) CPA (N = 18) CPB (N = 17)
Any AE 17 (94) 17 (100)
DAIDS Grade3 AEs 5 (28) 9 (53)
Drug-related AEsa 16 (89) 16 (94)
AEs leading to discontinuation of ribavirin 0 (0) 2 (12)
of all study treatments 0b (0) 7 (41)c
Serious AEs 1 (6) 9 (53)
Common AEsd Nausea 13 (72) 13 (76.5)
Diarrhoea 9 (50) 10 (59)
Vomiting 9 (50) 7 (41)
Ascites 0 8 (47)
Abdominal distension 5 (28) 1 (6)
Dizziness 1 (6) 5 (29)
Hepatic encephalopathy 0 5 (29)
Asthenia 7 (39) 7 (41)
Oedemia peripheral 4 (22) 5 (29)
Fatigue 4 (22) 3 (18)
Pruritus 8 (44) 5 (29)
Jaundice 5 (28) 8 (47)
Hyperbilirubinaemia 8 (44) 4 (24)
Anaemia 6 (33) 9 (53)
Insomnia 3 (17) 4 (24)
Ocular icterus 6 (33) 3 (18)
Decreased appetite 5 (28) 2 (12)
Urinary tract infection 0 4 (24)
AE, adverse event; CPA, Child-Pugh A; CPB, Child-Pugh B; DAIDS, NIH NIAID division of AIDS.
aInvestigator-assigned.
bOne CPA patient reported an adverse event of nausea that started 32 days before treatment and led to treatment discontinuation.
cOne CPB patient who was included in the database as having discontinued due to “other”, actually discontinued because of an adverse event.
dOccurring in at least 20% of patients in either group.
doi:10.1371/journal.pone.0168544.t003
Table 4. Plasma deleobuvir and faldaprevir trough concentrations.
CPA (N = 18; DBV 600 mg BID CPB (N = 17; DBV 400 mg BID)
n gMean (nmol/L) gCV% gMean/Da (nmol/L/mg) n gMean (nmol/L) gCV% gMean/Da (nmol/L/mg)
DBV Wk 1 16 12,700 120 21.2 15 9230 64 23.1
Wk 2 14 12,000 122 20.0 15 10,700 71 26.8
Wk 3 15 7100 196 11.8 14 9460 76 23.7
Wk 4 15 8390 109 14.0 11 12,500 36 31.3
gMean (ng/mL) gCV% gMean (ng/mL) gCV%
FDV Wk 1 16 8270 80 14 5660 56
Wk 2 14 8810 114 13 7840 64
Wk 3 15 6190 157 14 8850 61
Wk 4 14 5390 123 11 8590 43
DBV, deleobuvir; FDV, faldaprevir; gCV, coefficient of variation of the geometric mean; gMean, geometric mean; Wk, week
aDose normalized gMean trough concentrations.
doi:10.1371/journal.pone.0168544.t004
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weeks) to achieve SVR in patients with cirrhosis than in those without cirrhosis [2, 18, 19].
Response at treatment Week 4 appeared to predict SVR12 after 24 weeks of treatment,
although the small number of patients precluded statistical analysis. This was particularly nota-
ble in patients with moderate hepatic impairment (CPB), where none of the 4 patients having
Week 4 HCV RNA<25 IU.mL-1, but with target detected, achieved SVR12, whereas 8/9 (89%)
of those with undetectable HCV RNA at Week 4 achieved SVR12. It is conceivable that the
combination of faldaprevir and deleobuvir with ribavirin is not sufficient to prevent on-going
viral replication in patients where residual virus is detected at Week 4. Of note, with more
potent DAA combinations, detectable Week 4 HCV RNA is not predictive of treatment failure
[2, 18, 19]. Consistent with a more severe disease state, discontinuations, AEs and SAEs were
more common in patients with moderate hepatic impairment than in those with mild hepatic
impairment. The higher rates of AEs in CPB patients is likely related to these patients having
more severe liver disease and a more unstable condition. SAEs reported in CPB patients were
primarily related to worsening of the underlying disease (including hepatic cirrhosis, acute
hepatic failure, hepatic encephalopathy, ascites, haemorrhage and general physical health
deterioration).
In conclusion, in this small study in treatment-naïve and treatment-experienced patients
with chronic HCV genotype-1b infection and mild or moderate hepatic impairment, the
response to 24 weeks of treatment with faldaprevir, deleobuvir and ribavirin was not durable,
with 74% of patients achieving SVR4 but only 57% achieving SVR12. Since this study was initi-
ated, the HCV field has changed rapidly with the advent of new DAAs and all-oral DAA com-
binations. Because of this and based on the results of the phase 3 HCVerso1 and HCVerso2
trials [16], the development of the faldaprevir–deleobuvir combination has been terminated.
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